[ET Net News Agency, 14 December 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said Hansoh (Shanghai) Healthtech Company Limited (Hansoh Healthtech), a
wholly-owned subsidiary of the company, entered into an exclusive licence agreement with
Keros Therapeutics, Inc. (Nasdaq: KROS) (Keros).
Hansoh Healthtech obtained an exclusive licence from Keros to develop, manufacture and
commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau.
Hansoh Healthtech will be responsible for the development, regulatory approval and
commercialization of KER-050 in the territory and will pay a US$20 million upfront payment
and potential payments upon reaching development and commercial milestones of up to
US$170.5 million, plus double digit tiered royalties on net product sales. (RC)